Longevity & AgingPress Release

Serotonin Neurons May Quietly Switch Off the Urge to Move as Mice Age

Overactive serotonin neurons in the aging brain may suppress dopamine and the drive to move, even when muscles can still perform, a mouse study finds.

Saturday, November 14, 2026 0 views
Published in Lifespan.io
Article visualization: Serotonin Neurons May Quietly Switch Off the Urge to Move as Mice Age

Summary

Physical activity declines with age, and this study suggests the brain may be partly responsible. Researchers at the University of Aberdeen first confirmed that older people move less and more slowly than younger adults, and that aged mice show similar patterns. In mice, serotonin-producing neurons in the dorsal raphe, a brainstem region, fired more during the active dark phase as the animals aged. Stimulating these neurons reduced movement in young mice, while deleting the serotonin 5-HT2C receptor in middle-aged mice made them move farther and faster. The data point to a circuit in which serotonin activates inhibitory GABA neurons in the ventral tegmental area, which then dampen dopamine-driven motivation. The effect on movement was separate from changes in appetite or metabolism. The work suggests that some age-related inactivity reflects reduced drive rather than lost physical ability, though it comes from mice and is not yet a human treatment.

Detailed Summary

Why does activity fall as we age? Muscle weakness and chronic disease are part of the answer, but a new study from the University of Aberdeen, published in Metabolism – Clinical and Experimental, suggests the brain may also turn down the desire to move even when physical capacity remains. Because activity is closely tied to healthspan, understanding that brake matters.

The team first compared Scottish adults aged 17-30 with adults aged 50-70 using hip accelerometers worn for a week. Older participants moved less, moved more slowly and carried more body fat. Young and old mice assessed with similar measures showed matching differences, supporting mice as a reasonable model.

The researchers then gave mice d-fenfluramine, a drug that raises serotonin signaling. Movement, distance and speed fell during the dark phase, and the drug also briefly suppressed feeding, lowered energy expenditure and shifted fuel use toward fat, mimicking age-related changes. Dorsal raphe serotonin neurons were not fewer in older mice, but they fired more during the active dark phase and less in the light phase. Selectively stimulating these neurons cut movement in young mice without altering food intake, energy expenditure or fuel use. Knocking out the 5-HT2C receptor in 12- to 14-month-old mice increased distance and speed, again without metabolic changes.

Many ventral tegmental area neurons carry 5-HT2C and release inhibitory GABA. Tracing experiments linked dorsal raphe serotonin neurons to this area, suggesting a circuit in which serotonin activates GABA neurons that suppress dopamine neurons governing motivation and movement. Killing the serotonin neurons reversed the loss of activity.

The practical implication is that some age-related inactivity may be a motivational problem rather than a muscular one, which could eventually make 5-HT2C signaling a drug target. Caveats are substantial: these are mouse results, the human data were observational and descriptive, and serotonergic drugs have complex effects. Nothing here supports changing serotonin-related medication. Exercise remains the proven approach for maintaining function.

Key Findings

  • Older adults aged 50-70 moved less and more slowly than adults aged 17-30, while carrying more body fat.
  • Dorsal raphe serotonin neurons in older mice fired more during the active dark phase despite unchanged neuron numbers.
  • Selectively stimulating these neurons cut movement in young mice without changing appetite, energy expenditure or fuel use.
  • Deleting the 5-HT2C receptor in middle-aged mice increased distance traveled and speed.
  • Serotonin appears to activate inhibitory VTA neurons that dampen dopamine, lowering motivation to move.

Methodology

This is a news-style research summary from Lifespan.io of a University of Aberdeen study in Metabolism – Clinical and Experimental. Evidence combines a small observational human accelerometer comparison with mechanistic mouse experiments using drug, neuron stimulation, receptor knockout and viral tracing.

Study Limitations

Mechanistic evidence comes from mice, and the human component was descriptive and cannot show causation. The article text was truncated, so the final circuit details and dopamine experiments should be verified in the original paper. Translation to humans, and drug safety, remain untested.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: